What pre‑operative alpha‑1 blocker regimen should be used for patients undergoing stone surgery such as ureteroscopy or percutaneous nephrolithotomy?

Pre-operative Alpha-Blocker Regimen for Stone Surgery

For patients undergoing ureteroscopy (URS) or percutaneous nephrolithotomy (PCNL), alpha-blockers are NOT routinely recommended as pre-operative preparation for the surgical procedure itself, though they may be offered for medical expulsive therapy in select cases of conservative management.

Key Distinction: Medical Expulsive Therapy vs. Pre-operative Preparation

The 2025 EAU guidelines clearly address alpha-blockers in the context of medical expulsive therapy (MET) for conservative management of ureteral stones, not as routine pre-operative preparation for surgery 1. The guidelines state that alpha-blockers are efficacious for treatment of ureteral stones in patients amenable to conservative management, with greatest benefit for stones >5 mm in the distal ureter 1.

Similarly, the 2026 AUA guidelines recommend alpha-blockers for facilitating spontaneous stone passage in patients with ≤10 mm distal ureteral stones for approximately 30 days, not as pre-operative medication before planned surgery 2.

Evidence from Research Studies

While the guidelines don't recommend routine pre-operative alpha-blockers for stone surgery, recent research suggests potential benefits:

• For URS procedures: A 2025 study showed that two weeks of pre-operative silodosin (8 mg once daily) before URS improved success rates (81.82% vs 54.55%, p=0.006) and reduced complications 3. Another 2025 study found that preoperative alpha-blockers during flexible URS resulted in lower complication rates, higher stone access rates, and improved stone-free rates 4.

• Mechanism: A 2018 study demonstrated that preoperative alpha-blockade significantly reduces ureteral access sheath insertion force at both the ureterovesical junction and proximal ureter, with forces comparable to pre-stented patients 5.

• Elderly patients: A 2026 study in patients ≥60 years showed shorter operative duration, less need for ureteral dilation, and higher stone-free rates with preoperative tamsulosin 6.

Clinical Algorithm

If considering pre-operative alpha-blockers (off-guideline but evidence-supported):

1. For URS procedures: Consider 2 weeks of alpha-blocker therapy (silodosin 8 mg daily or tamsulosin 0.4 mg daily) before surgery 3, 7, 4

2. For PCNL: No evidence supports routine pre-operative alpha-blocker use; guidelines emphasize antibiotic prophylaxis instead 1

3. Patient selection: May be most beneficial for:

   • Elderly patients (≥60 years) 6
   • Patients without prior ureteral stenting
   • Cases where difficult ureteral access is anticipated

Important Caveats

• Guideline-recommended perioperative management focuses on:

  • Antibiotic prophylaxis: Single dose before URS is sufficient; extended course before PCNL for high-risk infection patients 1
  • Urine culture: Obtain before stone treatment to exclude/treat UTI 1
  • Antithrombotic management: Refer to internist for bleeding risk assessment 1

• The research supporting pre-operative alpha-blockers is relatively recent (2018-2026) and has not yet been incorporated into major guidelines 3, 7, 5, 6, 4

• Alpha-blockers are used off-label for this indication 1

• Post-operative alpha-blockers improve stent tolerability after URS 1